Free Access
Volume 24, Number 1, Janvier 2015
Page(s) 46 - 55
Section Mise Au Point / Update
Published online 15 January 2015
  • Cook D, Crowther M, Meade M, et al (2005) Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 33:1565–1571 [CrossRef] [PubMed] [Google Scholar]
  • Minet C, Lugosi M, Savoye PY, et al (2012) Pulmonary embolism in mechanically ventilated patients requiring computed tomography: Prevalence, risk factors, and outcome. Crit Care Med 40:3202–3208 [CrossRef] [PubMed] [Google Scholar]
  • Anderson FA, Wheeler HB, Goldberg RJ, et al (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151:933–938 [CrossRef] [PubMed] [Google Scholar]
  • Cohen AT, Agnelli G, Anderson FA, et al (2007) Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 98:756–764 [CrossRef] [PubMed] [Google Scholar]
  • Ma KA, Cohen E, Kahn SR (2014) Venous thromboembolism in hospitalized patients: An updated analysis of missed opportunities for thromboprophylaxis at a university-affiliated tertiary care center. Vasc Med 19:385–391 [CrossRef] [PubMed] [Google Scholar]
  • Ho KM, Chavan S, Pilcher D (2011) Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study. Chest 140:1436–1446 [CrossRef] [PubMed] [Google Scholar]
  • Hogue CW, Stearns JD, Colantuoni E, et al (2009) The impact of obesity on outcomes after critical illness: a meta-analysis. Intensive Care Med 35:1152–1170 [CrossRef] [PubMed] [Google Scholar]
  • Akinnusi ME, Pineda LA, El Solh AA (2008) Effect of obesity on intensive care morbidity and mortality: a meta-analysis. Crit Care Med 36:151–158 [CrossRef] [PubMed] [Google Scholar]
  • Prescott HC, Chang VW, O’Brien JM, et al (2014) Obesity and 1-year outcomes in older Americans with severe sepsis. Crit Care Med 42:1766–1774 [CrossRef] [PubMed] [Google Scholar]
  • Blokhin IO, Lentz SR (2013) Mechanisms of thrombosis in obesity. Curr Opin Hematol 20:437–444 [CrossRef] [PubMed] [Google Scholar]
  • Braekkan SK, Siegerink B, Lijfering WM, et al (2013) Role of obesity in the etiology of deep vein thrombosis and pulmonary embolism: current epidemiological insights. Semin Thromb Hemost 39:533–540 [CrossRef] [PubMed] [Google Scholar]
  • Hanley MJ, Abernethy DR, Greenblatt DJ (2010) Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49:71–87 [CrossRef] [PubMed] [Google Scholar]
  • PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, et al (2011) Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 364:1305–1314 [CrossRef] [PubMed] [Google Scholar]
  • Shorr AF, Williams MD (2009) Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. Thromb Haemost 101:139–144 [PubMed] [Google Scholar]
  • Douketis J, Cook D, Meade M, et al (2008) Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med 168:1805–1812 [CrossRef] [PubMed] [Google Scholar]
  • Pieracci FM, Barie PS, Pomp A (2006) Critical care of the bariatric patient. Crit Care Med 34:1796–1804 [CrossRef] [PubMed] [Google Scholar]
  • Stein PD, Beemath A, Olson RE (2005) Obesity as a risk factor in venous thromboembolism. Am J Med 118:978–980 [CrossRef] [PubMed] [Google Scholar]
  • Freeman AL, Pendleton RC, Rondina MT (2010) Prevention of venous thromboembolism in obesity. Expert Rev Cardiovasc Ther 8:1711–1721 [CrossRef] [PubMed] [Google Scholar]
  • Dellas C, Schäfer K, Rohm I, et al (2008) Absence of leptin resistance in platelets from morbidly obese individuals may contribute to the increased thrombosis risk in obesity. Thromb Haemost 100:1123–1129 [PubMed] [Google Scholar]
  • Chu NF, Spiegelman D, Hotamisligil GS, et al (2001) Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men. Atherosclerosis 157:495–503 [CrossRef] [PubMed] [Google Scholar]
  • Kabrhel C, Varraso R, Goldhaber SZ, et al (2009) Prospective study of BMI and the risk of pulmonary embolism in women. Obes Silver Spring Md 17:2040–2046 [CrossRef] [Google Scholar]
  • Severinsen MT, Overvad K, Johnsen SP, et al (2010) Genetic susceptibility, smoking, obesity and risk of venous thromboembolism. Br J Haematol 149:273–279 [CrossRef] [PubMed] [Google Scholar]
  • Di Nisio M, Di Iorio A, Porreca E, et al (2011) Obesity, poor muscle strength, and venous thromboembolism in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci 66:320–325 [CrossRef] [PubMed] [Google Scholar]
  • Allman-Farinelli MA (2011) Obesity and venous thrombosis: a review. Semin Thromb Hemost 37:903–907 [CrossRef] [PubMed] [Google Scholar]
  • López JA, Chen J (2009) Pathophysiology of venous thrombosis. Thromb Res 123(Suppl 4), S30–S34 [CrossRef] [Google Scholar]
  • Bardou M, Barkun AN (2013) Stress ulcer prophylaxis in the ICU: who, when, and how? Crit Care Med 41:906–907 [CrossRef] [PubMed] [Google Scholar]
  • Arnold DM, Donahoe L, Clarke FJ, et al (2007) Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Investig Med Médecine Clin Exp 30:E93–E102 [Google Scholar]
  • Fraisse F, Holzapfel L, Couland JM, et al (2000) Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 161, (4 Pt 1) 1109–1114 [CrossRef] [PubMed] [Google Scholar]
  • Cook D, Douketis J, Meade M, et al (2008) Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. Crit Care Lond Engl 12:R32 [CrossRef] [Google Scholar]
  • Lilly CM, Liu X, Badawi O, et al (2014) Thrombosis prophylaxis and mortality risk among critically ill adults. Chest 146:51–57 [CrossRef] [PubMed] [Google Scholar]
  • Kahn SR, Lim W, Dunn AS, et al (2012) Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl), e195S–e226S [CrossRef] [PubMed] [Google Scholar]
  • Cook DJ, Crowther MA (2010) Thromboprophylaxis in the intensive care unit: focus on medical-surgical patients. Crit Care Med 38(2 Suppl), S76–S82 [CrossRef] [PubMed] [Google Scholar]
  • Gould MK, Garcia DA, Wren SM, et al (2012) Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl), e227S–e277S [CrossRef] [PubMed] [Google Scholar]
  • Bergmann J-F, Cohen AT, Tapson VF, et al (2010) Venous thromboembolism risk and prophylaxis in hospitalised medically ill patients. The ENDORSE Global Survey. Thromb Haemost 103:736–748 [CrossRef] [Google Scholar]
  • García-Olivares P, Guerrero JE, Galdos P, et al (2014) PROFETEV study: prophylaxis of venous thromboembolic disease in critical care units in Spain. Intensive Care Med 40:1698–1708 [CrossRef] [PubMed] [Google Scholar]
  • Erstad BL (2004) Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Med 30:18–32 [CrossRef] [PubMed] [Google Scholar]
  • Singh K, Podolsky ER, Um S, et al (2012) Evaluating the safety and efficacy of BMI-based preoperative administration of lowmolecular-weight heparin in morbidly obese patients undergoing Roux-en-Y gastric bypass surgery. Obes Surg 22:47–51 [CrossRef] [PubMed] [Google Scholar]
  • Bounameaux H, de Moerloose P (2004) Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost JTH 2:551–554 [CrossRef] [Google Scholar]
  • Lim W (2010) Using low molecular weight heparin in special patient populations. J Thromb Thrombolysis 29:233–240 [CrossRef] [PubMed] [Google Scholar]
  • Bakirhan K, Strakhan M (2013) Pharmacologic prevention of venous thromboembolism in obese patients. J Thromb Thrombolysis 36:247–257 [CrossRef] [PubMed] [Google Scholar]
  • Priglinger U, Delle Karth G, Geppert A, et al (2003) Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill? Crit Care Med 31:1405–1409 [CrossRef] [PubMed] [Google Scholar]
  • Imberti D, Legnani C, Baldini E, et al (2009) Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). Thromb Res 124:667–671 [CrossRef] [PubMed] [Google Scholar]
  • Rowan BO, Kuhl DA, Lee MD, et al (2008) Anti-Xa levels in bariatric surgery patients receiving prophylactic enoxaparin. Obes Surg 18:162–166 [CrossRef] [PubMed] [Google Scholar]
  • Simone EP, Madan AK, Tichansky DS, et al (2008) Comparison of two low-molecular-weight heparin dosing regimens for patients undergoing laparoscopic bariatric surgery. Surg Endosc 22:2392–2395 [CrossRef] [PubMed] [Google Scholar]
  • Freeman A, Horner T, Pendleton RC, Rondina MT (2012) Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol 87:740–743 [CrossRef] [PubMed] [Google Scholar]
  • Samama MM, Cohen AT, Darmon JY, et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341:793–800 [CrossRef] [PubMed] [Google Scholar]
  • Kucher N, Leizorovicz A, Vaitkus PT, et al (2005) Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. Arch Intern Med 165:341–345 [CrossRef] [PubMed] [Google Scholar]
  • Imberti D, Baldini E, Pierfranceschi MG, et al (2014) Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study). Obes Surg 24:284–291 [CrossRef] [PubMed] [Google Scholar]
  • Stroh C, Luderer D, Weiner R, et al (2012) Actual situation of thromboembolic prophylaxis in obesity surgery: data of quality assurance in bariatric surgery in Germany. Thrombosis 2012:209052 [CrossRef] [PubMed] [Google Scholar]
  • Cumbo-Nacheli G, Samavati L, Guzman JA (2011) Bioavailability of fondaparinux to critically ill patients. J Crit Care 26:342–346 [CrossRef] [PubMed] [Google Scholar]
  • Shepherd MF, Rosborough TK, Schwartz ML (2003) Heparin thromboprophylaxis in gastric bypass surgery. Obes Surg 13:249–253 [CrossRef] [PubMed] [Google Scholar]
  • Quebbemann B, Akhondzadeh M, Dallal R (2005) Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients. Obes Surg 15:1221–1224 [CrossRef] [PubMed] [Google Scholar]
  • Goldhaber SZ, Leizorovicz A, Kakkar AK, et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167–2177 [CrossRef] [PubMed] [Google Scholar]
  • Cohen AT, Spiro TE, Büller HR, et al (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368:513–523 [CrossRef] [PubMed] [Google Scholar]
  • Limpus A, Chaboyer W, McDonald E, Thalib L (2006) Mechanical thromboprophylaxis in critically ill patients: a systematic review and meta-analysis. Am J Crit Care Off Publ Am Assoc Crit-Care Nurses 15:402–410 [Google Scholar]
  • CLOTS (Clots in Legs Or sTockings after Stroke) Trials Collaboration, Dennis M, Sandercock P, et al (2013) Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet 382:516–524 [CrossRef] [PubMed] [Google Scholar]
  • Vignon P, Dequin PF, Renault A, et al (2013) Intermittent pneumatic compression to prevent venous thromboembolism in patients with high risk of bleeding hospitalized in intensive care units: the CIREA1 randomized trial. Intensive Care Med 39:872–880 [CrossRef] [PubMed] [Google Scholar]
  • Rajasekhar A, Streiff MB (2013) Vena cava filters for management of venous thromboembolism: a clinical review. Blood Rev 27:225–241 [CrossRef] [PubMed] [Google Scholar]
  • Konstantinides SV, Torbicki A, Agnelli G, et al (2014) 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 35:3033–3069 [CrossRef] [PubMed] [Google Scholar]
  • De A, Roy P, Garg VK, Pandey NK (2010) Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery. Blood Coagul Fibrinolysis Int J Haemost Thromb 21:57–61 [CrossRef] [Google Scholar]
  • Cade JF (1982) High risk of the critically ill for venous thromboembolism. Crit Care Med 10:448–450 [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.